• Icon International Neuroendocrine Cancer Alliance

  • Mail: post@incalliance.org

Category: News

Inca blog Bill ENETS 1
Notes from ENETS 2017

 

Blog post by Bill Claxton.
Barcelona 8-10 March

Notes from ENETS 2017

ENETS is the world’s premier conference on neuroendocrine cancer, this year attended by more than 1200 physicians and a few dozen patient advocates. The ENETS conference highlighted the latest in understanding in tumor biology as well as offering the most current and relevant aspects of neuroendocrine tumor (NET) advances in diagnostics and therapeutics.

 

Bill Claxton, one of the founders of CNETS Singapore, is a well known patient advocate. Bill has been involved in video recording of many international carcinoid and neuroendocrine tumor conferences. These videos provide an excellent resource for patients, caregivers and physicians. Read more from Bill, Good news for NET Cancer
Learn more; Webinar Series with NET Cancer specialists and Webinar for Lung NETs

Read More
header-inca-blog-news-webinar
NET Cancer webinar series

NET Cancer specialist at Asia Pacific Neuroendocrine Tumor Society (APNETS) conference 2016.

Webinar Series with NET Cancer specialists

 A series of webinars from NET Cancer specialist. Produced by CNETS SG at Asia Pacific Neuroendocrine Tumor Society (APNETS) conference. Many of the talks are of particularly interest to NET Cancer advocates, and also to patients and caregivers.  View presentations from; Marianne Pavel, Rodney Hicks, Sugandha Dureja, Frank Ulrich Pape, David Tai, Kjell Oberg and many more. 

Find more from the CNETS Ipsen Webinar Series at https://itr8.wistia.com/projects/4eujigyhr0

Thanks to Carcinoid & Neuroendocrine Tumor Society of Singapore, CNETS SG, for sharing and producing the webinar. Also thanks to Ipsen Pharma for their support creating these videos.

Read More
Header Inca Lets talk
Let’s Talk About NETs

Unfortunately in the crowded space of health promotion amongst not for profits and patient groups, less common cancers such as NET Cancer (neuroendocrine cancer) do not get the attention that they deserve and need.

Let’s Talk About NETs” this World NET Cancer Day Nov 10.

 

This year we propose that we simplify our complicated message and with the help of our patients and supporters around the country (and around the globe) spread the news through “Let’s Talk About NETs”.

Read More
inca header plovdiv
4th INCA NET Patient Advocacy Summit

For a fourth time since 2012 INCA brings together NET patient advocate leaders from around the globe to learn about the latest treatment developments and research, as well as share best practices and build common platforms.

4th INCA NET Patient Advocacy Summit in Plovdiv (Bulgaria), 11-13 July 2016.

Read More
inca header survey
First Global Neuroendocrine Tumor Patient Survey Results Published in Journal of Global Oncology

  “Patient-Reported Burden of a Neuroendocrine Tumor (NET) Diagnosis: Results From the First Global Survey of Patients With NETs” - a collaborative effort between the International Neuroendocrine Cancer Alliance (INCA) and Novartis, was published in the Journal of Global Oncology. The Global NET Patient Survey is the first large, global initiative that attempts to characterize…

Read More
ron1 web
INCA MEETING FEATURES CFCF RESEARCHER: FOCUS ON PRRT

 

Blog post by Ron Hollander.

The International Neuroendocrine Cancer Alliance (INCA) held its annual  Summit and Member meeting in Oxford, England. The assembled representatives from NET groups in 18 nations focused on ways to spread awareness, assist NET groups, and support research for NET patients worldwide. 

INCA summit Oxford
(L-R) INCA Secretary Jo Grey (UK) – Association for Multiple Endocrine Neoplasia Disorders (AMEND); CFCF Funded Researcher Tim Meyer, MD, PhD – UCL Cancer Institute, University College London; INCA President Teodora Kolarova (Bulgaria) – APOZ & Friends; Ron Hollander – CFCF Executive Director; Josh Mailman – President of NorCal CarciNET Community; Yoshiyuki Majima (Japan) – PanCan

Read More
bill1 web
Good news for NET Cancer

 

Blog post by Bill Claxton.

Good news from Vienna, ECC 2015, the European Cancer Congress,
announced by Philippe Ruszniewski, MD, head of gastroenterology and pancreatology at Beaujon Hospital, in Clichy, France.

“Treatment with the novel peptide receptor radionuclide therapy (PRRT) Lutathera significantly increased progression-free survival (PFS) over octreotide LAR (Sandostatin) in patients with advanced midgut neuroendocrine tumors (NETs), according to findings from the phase III NETTER-1 trial presented at the 2015 European Cancer Congress.”
Medical abstract is here (www.europeancancercongress) and a press release is here (www.onclive.com).

 

Read More
Copyright © 2015 International Neuroendocrine Cancer Alliance. All right reserved.
Make a Donation
Paybal button